Gut microbial CAZymes markers for depression

Gut microbial CAZymes markers for depression | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Gut microbial CAZymes markers for depression peng zheng, Peijun Xie, Xingyu Zhou, Yifan Li, Jing Wu, Hanping Zhang, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3223945/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Mar, 2024 Read the published version in Translational Psychiatry → Version 1 posted 7 You are reading this latest preprint version Abstract Major depressive disorder (MDD) is a serious mental illness, characterized by disturbances of gut microbiome, it is required to further explore how the carbohydrate-active enzymes (CAZymes) were changed in MDD. Here, using the metagenomic data from patients with MDD (n = 118) and heath controls (HC, n = 118), we found that the whole CAZymes signatures of MDD were significantly discriminated from that in HC. α-diversity indexes of the two groups were also significantly different. The patients with MDD were characterized by enriched Glycoside Hydrolases (GHs) and Polysaccharide Lyases (PLs) relative to HC. A panel of makers composed of 9 CAZymes mainly belonging to GHs enabled to discriminate the patients with MDD and HC with AUC of 0.824. In addition, this marker panel could classify blinded test samples from the two groups with an AUC of 0.736. Moreover, we found that baseline 4 CAZymes levels also could predict the antidepressant efficacy after adjusted confounding factors and times of depressive episode. Our findings showed that MDD was associated with disturbances of gut CAZymes, which may help to develop diagnostic and predictive tools for depression. Biological sciences/Psychology Health sciences/Biomarkers Major depressive disorder Gut microbiome CAZyme-encoding genes CAZymes Biomarker Figures Figure 1 Figure 2 Figure 3 Introduction Major depressive disorder (MDD) is a serious and disabling mental illness, affecting up to 15% of the general population [ 1 ]. Currently, there are many theories about the pathogenesis of MDD, but they still can't reveal its whole picture. Current antidepressants developed based on the existing theories can only make 30–50% of patients achieve clinical remission [ 2 , 3 ]. In addition, clinically, the diagnosis of depression is mainly based on its clinical symptoms and scales. In developing countries, due to lack of professional psychiatrists, and the missed diagnosis and misdiagnosis rate of MDD is still high [ 4 ]. Therefore, it is of great clinical value to reveal the new potential molecular mechanisms of depression and identify the potential biomarkers for MDD. Gut microbiome, an integral part of host biology, harbors about 90 families of carbohydrate-active enzymes (CAZymes) in healthy humans [ 5 – 7 ]. By contrast, there are only 4 enzyme families of the human genome, which only degrades starch, trehalose, and sugars [ 8 ]. In human, the more complex the structure of carbohydrates, the more diverse the enzyme system is needed. Thus, the gut microbiome enables to decompose complex fibers, and convert sugar units into energy to maintain the host’s health [ 9 , 10 ]. In recent years, increasing clinical and basic studies showed that gut microbiome enables to substantially modulate the brain function and behaviors through microbiome-gut-brain (MGB) axis [ 11 ]. Meanwhile, disturbances of gut microbiome were implicated with development of mental diseases, such as autism, anxiety and schizophrenia [ 12 – 14 ]. In regarding of MDD, similar phenomenon was also observed. For examples, using the well-matched clinical samples, we found that patients with MDD were characterized by enriched the Bacteroidetes species relative to HC [ 15 ], showing a disease specific manner relative to patients with bipolar disorder [ 16 ]. As Bacteroidetes have more CAZymes-encoding genes [ 8 ], we speculate that patients with MDD may be accompanied by alternations of gut microbial CAZymes. To test this hypothesis, using the whole-genome shotgun metagenomics method, we compared the microbial CAZymes signatures of patients with MDD and HC. Multivariate statistical method was used to explore the differences of gut microbial CAZymes signatures between the two groups. Meanwhile, the diagnostic and predictive values of candidate CAZymes biomarkers were also evaluated in MDD. Methods Ethics and participants Ethical approval was obtained from the Human Research and Ethics Committee of Beijing Anding Hospital (#2017-24), Capital Medical University (China) aligning with the Declaration of Helsinki. The study design complied with all relevant ethical regulations, and all participants provided written informed consent. Sample collection Totally, 311 individuals (aged 18 to 50 years old) were included in this study, including 155 HC and 156 patients with MDD. These samples were obtained from previous metagenomic cohort [ 15 ]. According to the Chinese version of the Mini-International Neuropsychiatric Interview (MINI), all MDD patients met the standard of DSM-IV. The Hamilton Depression Rating Scale (HAMD) and quick inventory of depressive symptomatology (QIDS) were used to evaluate the depressive severity and manic symptoms of MDD and BD. Patients with HAMD score of 0–3 is defined as normal, 4–7 as marginal, 8–15 as mild, 16–26 as moderate, and higher than 27 as severe [ 17 ]. A QIDS score of < 6 is defined as normal, 6–10 as mild, 11–15 as moderate, and higher than 16 as severe [ 18 ]. Participants who used anti-depressant before collection were excluded in this study. Other exclusion criteria included: (1) History of other mental disorders; (2) suffering from chronic inflammatory disease, diabetes, cardiovascular disease, thyroid disease or cancer; (3) alcohol or drug abuse, acute poisoning; (4) pregnancy or breastfeeding; (5) current administration of antibiotics or long-term use of probiotics. DNA extraction and sequencing Fecal samples were stored at − 20°C immediately after collection in the recruitment center, and then wrapped in dry ice and transported to the cryopreservation center. The total genomic DNA of fecal samples was extracted by E.Z.N.A.® Soil DNA Kit (Omega Bio-tek, Norcross, GA, USA) according to the manufacturer’s instructions. Then the concentration and purity of the extracted DNA were determined with TBS-380 (Turner BioSystems, Sunnyvale, CA, USA) and NanoDrop 2000 (Thermo-Fisher, Waltham, MA, USA) fluorometry and spectrophotometry respectively, and quality was checked by 1% agarose gel electrophoresis. Paired-end library was constructed after fragmented DNA into an average size of about 300 bp using focused ultrasonication (Covaris M220, Woburn, MA, USA). Then the paired-end sequencing was performed on an Illumina NovaSeq sequencer (Illumina Inc., San Diego, CA, USA). Raw fastq data were quality filtered based on Sickle ( https://github.com/najoshi/sickle ), then low-quality reads (length < 50 bp, or quality value < 20, or having N bases) were removed. Reads were aligned to the human genome by BWA ( http://bio-bwa.sourceforge.net ), and any hit associated with the reads and their mated reads were removed. Metagenomics data were assembled using MEGAHIT, and contigs with length ≥ 300 bp were selected as the final assembled result. Open reading frames (ORFs) from each assembled contig were predicted using MetaGene [ 19 ]. All predicted genes with a 95% sequence identity were clustered using CD-HIT [ 20 ]. Reads after quality control were mapped to the representative sequences with 95% identity using SOAPaligner ( http://soap.genomics.org.cn/ ). Annotation and initial analysis The non-redundant gene sets were aligning CAZymes database ( http://www.cazy.org/ ) based on hmmscan (hmmer 3.0), and the cutoff e-value is set to 1e − 5 . Gene expression was reflected by the RPKM value: $$RPK{M}_{i}=\frac{{R}_{i}\times {10}^{6}}{{L}_{i}\times {\sum }_{1}^{n}\left({R}_{j}\right)}$$ Where R i is the abundance value of Gene i in a sample (the reads number aligned to Gene i ), L i represents the nucleotide length of Gene i , \({\sum }_{1}^{n}\left({R}_{j}\right)\) represents the sum of reads corresponding to all genes in the sample. CAZymes analysis α-diversity analysis including Simpson 1/D, Shannon H’, Menhinick, Margalef and Berger-Parker indexes [ 21 , 22 ] was conducted and visualized using the vegan and fossil packages in R, respectively. Principal coordinates analysis (PCoA) was used to visually evaluate the overall difference and similarity of CAZymes between MDD and HC groups [ 23 ]. The permutational multivariate analysis of variance (PERMANOVA) was used to test group differences. The differential CAZymes between the two groups were identified using wilcoxon rank sum test ( p 1% as diagnostic markers, then a 5-fold cross-validation was performed to verify the reliability [ 24 ]. The receiver operating characteristic (ROC) curve was obtained (SPSS V.19.0) for the display of the constructed models, then the area under the ROC curve (AUC) was used to designate the ROC effect. Co-occurrence among CAZymes was calculated based on the RPKM by pearson’s correlation coefficient ( p < 0.05). The network layout was calculated and visualized using a circular layout by the Cytoscape software (version 3.1.1). Longitudinal analysis We used a linear mixed-effects model to examine the longitudinal association of gut CAZymes with disease severity (HAMD and QIDS), adjusted for the demographic (age, gender and educational background), anthropometric (BMI), times of depressive episode and medication. Associations were expressed as the difference in HAMD or QIDS score (in SD units) per SD difference in each CAZymes, and p value < 0.05 was considered statistically significant. Results Demographic and clinical data of the recruited subjects. In this study, gut metagenome data from 311 participants were obtained from our previous studies. All patients with MDD (n = 118) were unmedicated at baseline, and there was no statistic difference of demographic characteristics in gender, age or BMI between two groups (Table. S1). In addition, an independent validation set (n = 75), whose clinical characteristics did not exactly match, was adopted to verify the diagnostic generalizability of CAZymes markers. In addition, 45 MDD subjects were included in the longitudinal follow-up at 3 time points. The clinical scores were used to quantify the efficacy of antidepressants (Table. S2). Alternations of CAZymes signatures in MDD Here, we obtained 23578.431 million paired-end reads on average based on shotgun metagenomic sequencing. We detected a total of 518 CAZymes, and then included 456 CAZymes (prevalence > 10%, mean RPKM > 0.01%) for subsequent analysis. Initially, using the multivariate statistical analysis, we sought to explore whether the whole CAZymes signatures of MDD group were significantly different from that in the HC group. Consequently, we observed significant differences of the whole CAZymes signatures between two group based on Pcoa (bray-curtis distance, permutation test, p = 0.002, Fig. 1 a), and in the first and second principal component (PC1) (Mann-Whitney U test, p = 0.004, Fig. 1 b). Next, we compared the α-diversity of CAZymes signatures between MDD and HC groups. We found that patients with MDD accompanied by 2 increased indexes (Simpson 1/D and Shannon H’) and 4 decreased indexes (Menhinick, Margalef, Berger-Parker and Chao 1) (Fig. 1 c). In addition, using the wilcoxon rank sum test, we totally identified 83 CAZymes responsible for discriminating the MDD and HC groups (Fig. 1 d). These differentially expressed CAZymes mainly involved in Glycoside Hydrolases (GHs, MDD vs HC, 47.0% vs 14.5%), Glycosyl Transferases (GTs, MDD vs HC, 3.6% vs 4.8%), Polysaccharide Lyases (PLs, MDD vs HC, 12.0% vs 2.4%), Carbohydrate Esterases (CEs, MDD vs HC, 4.8% vs 2.4%) and Carbohydrate-Binding Module (CBMs, MDD vs HC, 3.6% vs 4.8%). Our results showed that the utilization of plant and animal carbohydrates in MDD and HC may be in a balance state. However, compared with the carbohydrate utilization capacity of plants and animals, MDD microbiota shows a higher preference for mucin utilization (Fig. 1 e). Diagnostic gut CAZymes markers for MDD A volcano plot with Fold change was applied to identify the specific CAZymes differences between the two groups. The two groups differed in 9 CAZymes markers (Fig. 2 a). Using the random forest model, we identified 9 candidate CAZymes markers for MDD. The results showed that 6GHs (GH20, GH43_24, GH43_4, GH51 and GH95) and 1PL (PL12_1) were significantly increased in MDD group relative to HC group, while 1CBM (CBM37) was decreased (Fig. 2 b and Table. S3). We found that a marker panel including this 9 CAZymes enabled to effectively discriminate the samples from MDD and HC, yielding an AUC value of 0.824 (95% confidence interval (CI), 0.772 to 0.876) (Fig. 2 c). In addition, the 5-fold cross validation was performed to further test the diagnostic performance. Then, a validation set was used to independently confirm the diagnostic performance of this marker panel. Consequently, we found that the this CAZymes panel could discriminate blinded test samples from the two groups with an AUC of 0.736 (95% CI, 0.623–0.849), respectively (Fig. 2 c). Co-occurrence network of CAZymes markers To explore the potential interaction among CAZymes in MDD, pearson correlation analysis was performed. Here, co-occurrence network depicted the associations (pearson r 0.2, p value < 0.05) among the MDD-related CAZymes (Fig. 2 d). Interestingly, 6 GHs including (GH43_24, GH43_4, GH43_7, GH95, GH20 and GH51) generated a covarying cluster, and the members within GHs cluster were negatively correlated to CBM37. In addition, a similar clustering pattern was identified after adding HC samples (Figure S1 ). Predictive CAZymes markers for MDD Next, 45 patients with MDD who were treated with antidepressants were followed up every two weeks (2 weeks, 4 weeks and 6 weeks after treatment) (Figure S2 a). To evaluate the relationship between gut CAZymes and the efficacy of antidepressants, we performed a linear mixed-effects model to examine the longitudinal association of CAZymes markers with MDD disease severity (HAMD, QIDS). A total of 5 gut CAZymes was positively or inversely associated with at least one clinical score (Fig. 3 a, b), including 4 GHs (GH43_24, GH43_4, GH20 and GH51) and 1PL (PL12_1). We found that the GH51 (per SD unit) showed a significant inverse association with HAMD (2w: estimated value − 0.078, 95% CI: -0.115, -0.040; 4w: estimated value − 0.085, 95% CI: -0.131, -0.040; 6w: estimated value − 0.048, 95% CI: -0.089, -0.007) and QIDS (2w: estimated value − 0.035, 95% CI: -0.069, -0.002; 4w: estimated value − 0.041, 95% CI: -0.077, -0.005). Consistently, PL12_1 was also found to be inversely associated with HAMD scores at 4, 6-weeks after antidepressants (4w: estimated value − 0.364, 95% CI: -0.631, -0.097; 6w: estimated value − 0.341, 95% CI: -0.582, -0.099), and 6-weeks QIDS (6w: estimated value − 0.250, 95% CI: -0.455, -0.046). In addition, 2 GHs showed a positive association with 2-week HAMD scores (GH43_24: estimated value 0.063, 95% CI: 0.007, 0.118; GH43_4: estimated value 0.054, 95% CI: 0.002, 0.106). Moreover, GH20 was found to be only related to the 6-week HAMD scores. However, none of GHs or PLs were found to be associated with clinical score at baseline group (Figure S2 b). Discussion Clinical and basic studies have shown the link between gut microbiome and MDD. As the fraction of gut microbiome containing the gene coding for CAZymes, here we charactered how the CAZymes changed in the MDD relative to HC. Interestingly, we found that MDD was associated with enriched Glycoside Hydrolases and Polysaccharide Lyases. A random forest model constructed by 9 CAZymes could effectively distinguish patients with MDD and HC, then the diagnostic performance of this CAZymes panel was independently verified. Meanwhile, based on linear mixed-effects analysis, we found that 4 CAZymes could predict the therapeutic effects in the patients treated with antidepressants. Our research provides new ideas for the accurate diagnosis and treatment of depression. The metagenome data suggest that the gut microbiota of MDD have a greater mucin-utilization capacity relative to HC. It may because of the high concentration of Bacteroides in MDD population. In addition, the increased availability of mucin may weaken the mucous layer of the intestinal wall, and some Bacteroides can degrade mucin during survival, such as B. thetaiotaomicron , B. fragilis , as a result, harmful molecules in MDD are more likely to cross the gut and enter the circulatory or endocrine system [ 25 ]. Alternations of gut microbiome were closely related to depression. In the past, we and other teams focused on exploring how the gut bacteria and viruses changed in MDD [ 15 , 26 , 27 ]. In addition, using fecal bacteria transplantation and probiotic intervention, preliminary evidences showed that disturbances of gut microbiome may attribute to development of depression by regulating the MGB axis’ metabolism [ 28 , 29 ].These studies lay a foundation for further study of the role of gut microbiome in depression. Here, we identified the differentially expressed CAZymes in the patients with MDD relative to HC, hoping to further understand the function of gut microbiome in depression from this new point. Here, we found MDD is substantially linked with alternations of CAZymes relative to HC. Compared to HC, the MDD was characterized by enriched Glycoside Hydrolases and Polysaccharide Lyases. Given Bacteroides, especially Bacteroides thetaiotaomicron and Bacteroides ovatus, dedicate about 6% of their genomes to encode these two CAZymes [ 8 ]. These results suggesting that alternations of Bacteroides species was a hallmark of MDD, which was consistent with our previous studies [ 15 , 16 ]. In addition, we found that the CAZymes has potential diagnostic and predictive value in MDD. For example, CAZymes maker panel enable discriminating the MDD and HC with the values of 0.824, suggesting that it has potential clinical transformation value. Clinically, predicting the efficacy of antidepressants remains challenging prior to antidepressant medication, thus inevitably, the trial and error of experience lies in the replacement of new drugs. Here, we found that markers belonging to Glycoside Hydrolases increased in baseline MDD relative to HC. Interestingly, the baseline level of GH51 was negatively correlated with HAMD (2, 4 and 6weeks) and QIDS (2 and 4weeks) scores. Consistently, PL12_1 was also negatively correlated with these two clinical scores of 6weeks. An enzyme (α-L-arabinofuranosidase) in the GH51 family, encoded by two dominant Bacteroides (B. ovatus V975 and B. thetaiotaomicron VPI-5482) [ 30 , 31 ].Another CAZyme (PL12_1) contains 2 types of heparin lyase, which were found to be encoded by B. stercoris HJ-15 and B. thetaiotaomicron VPI-5482 [ 32 , 33 ].These results suggesting alternations between drugs and biological functions of Bacteroides involved in antidepressant effects. Given CAZymes could be detected in feces, it lays a foundation for the development of noninvasive diagnostic and predictive kits. Our study has the following shortcomings: (1) although a relatively large sample size is used to identify CAZymes as candidate markers, this result still needs to be independently verified by a large multi-center sample; (2) In depth study of the function of CAZymes is expected to further understand the roles of gut microbiome in the pathophysiological mechanisms of MDD; (3) Since CAZymes are mainly involved in the digestion of polysaccharides, it is also worth exploring how to formulate an individualized diet which is more suitable for the microecological health of MDD; (4) Future researches to explore whether intervention of CAZymes has potential therapeutic effects in MDD are required. In this study, using well-characterized cross-section and longitudinal clinical samples, we provided evidences that MDD was associated with disturbances of gut CAZymes. Moreover, we found that the CAZymes markers can be used to diagnose the patients with MDD and predict antidepressant effects. Our findings suggest that alternations of CAZymes may be a new entry point to understand the roles of gut microbiome in the development of MDD. Declarations ACKNOWLEDGEMENTS Fundings: This work was supported by the Chongqing Science and Technology Committee (cstc2021jcyj-msxmX0096), the Natural Science Foundation Project of China (81971296, 82171523, 82171526 and 82201688), the National Key R&D Program of China (2017YFA0505700), Beijing Talents Project (2020A38), Projects of International Cooperation and Exchanges NSFC (81820108015), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT320002), Chongqing Science &Technology Commission (cstc2019 jcyjjqX0009, cstc2021 jscx-msxm0026), Chongqing Talents Plan for Young Talents (CQYC202105017), Program for Youth Innovation in Future Medicine, Chongqing Medical University, China Postdoctoral Science Foundation (2022MD713717, 2021TQ0396, 2021MD703928). Availability of data and material: The metagenomic sequencing data were deposited in the China National GeneBank DataBase (CNGBdb) (https://db.cngb.org/; project ID: CNP0001162). Ethics approval and consent to participate: The study was approved by the Human Research and Ethics Committee of Beijing Anding Hospital of Capital Medical University (#2017-24). Conflict of interests: The authors declare that they have no conflict of interests. AUTHOR CONTRIBUTIONS Designed the experiments: P.Z. and J.Y. Performed the metagenomic analysis: P.J.X., X.Y.Z., Y.F.L., J.W., Y.H. and H.P.Z. Analyzed the metagenomic data: P.J.X., X.Y.Z., Y.F.L., O.O., J.J.Z., Z.L.S., M.L., G.F.Z., Y.W. and J.Y. Drafted the paper: P.J.X., X.Y.Z. Revised the paper for intellectual content: J.Y. and P.Z. References Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136–151. Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J Clin Psychiatry 2020; 81. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–151. Karamustafalioğlu O. Major depressive disorder, mental health care, and the use of guidelines in the Middle East. J Clin Psychiatry 2010; 71 Suppl E1: e07. Bhattacharya T, Ghosh TS, Mande SS. Global Profiling of Carbohydrate Active Enzymes in Human Gut Microbiome. PLoS One 2015; 10: e0142038. Tarrah A, Pakroo S, Lemos Junior WJF, Guerra AF, Corich V, Giacomini A. Complete Genome Sequence and Carbohydrates-Active EnZymes (CAZymes) Analysis of Lactobacillus paracasei DTA72, a Potential Probiotic Strain with Strong Capability to Use Inulin. Curr Microbiol 2020; 77: 2867–2875. El Kaoutari A, Armougom F, Gordon JI, Raoult D, Henrissat B. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat Rev Microbiol 2013; 11: 497–504. Wardman JF, Bains RK, Rahfeld P, Withers SG. Carbohydrate-active enzymes (CAZymes) in the gut microbiome. Nat Rev Microbiol 2022; 20: 542–556. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. Bmj 2018; 361: k2179. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 2015; 64: 1744–1754. Morais LH, Schreiber HLt, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 2021; 19: 241–255. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv 2019; 5: eaau8317. Sharon G, Cruz NJ, Kang DW, Gandal MJ, Wang B, Kim YM et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell 2019; 177: 1600–1618.e1617. Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression - A systematic review. Clin Psychol Rev 2021; 83: 101943. Yang J, Zheng P, Li Y, Wu J, Tan X, Zhou J et al. Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Sci Adv 2020; 6. Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B et al. Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Adv Sci (Weinh) 2020; 7: 1902862. Furukawa TA. Assessment of mood: guides for clinicians. J Psychosom Res 2010; 68: 581–589. Wang PS, Simon GE, Avorn J, Azocar F, Ludman EJ, McCulloch J et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. Jama 2007; 298: 1401–1411. Noguchi H, Park J, Takagi T. MetaGene: prokaryotic gene finding from environmental genome shotgun sequences. Nucleic Acids Res 2006; 34: 5623–5630. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 2012; 28: 3150–3152. Cherchi A, Da Pelo S, Ibba A, Mana D, Buosi C, Floris N. Benthic foraminifera response and geochemical characterization of the coastal environment surrounding the polluted industrial area of Portovesme (South-Western Sardinia, Italy). Mar Pollut Bull 2009; 59: 281–296. Begum R, Majagi SH, Vijaykumar K. Ants species richness and diversity in relation to different ecological habitat in selected localities of the semi-arid region of Karnataka, India. Environ Monit Assess 2021; 193: 145. Doan T, Hinterwirth A, Worden L, Arzika AM, Maliki R, Abdou A et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med 2019; 25: 1370–1376. Rahimian F, Salimi-Khorshidi G, Payberah AH, Tran J, Ayala Solares R, Raimondi F et al. Predicting the risk of emergency admission with machine learning: Development and validation using linked electronic health records. PLoS Med 2018; 15: e1002695. Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 2020; 69: 2232–2243. Pearson-Leary J, Zhao C, Bittinger K, Eacret D, Luz S, Vigderman AS et al. The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats. Mol Psychiatry 2020; 25: 1068–1079. Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2022; 76: 665–680. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 2016; 21: 786–796. Yang Z, Li J, Gui X, Shi X, Bao Z, Han H et al. Updated review of research on the gut microbiota and their relation to depression in animals and human beings. Mol Psychiatry 2020; 25: 2759–2772. Whitehead TR. Nucleotide sequences of xylan-inducible xylanase and xylosidase/arabinosidase genes from Bacteroides ovatus V975. Biochim Biophys Acta 1995; 1244: 239–241. Luis AS, Briggs J, Zhang X, Farnell B, Ndeh D, Labourel A et al. Dietary pectic glycans are degraded by coordinated enzyme pathways in human colonic Bacteroides. Nat Microbiol 2018; 3: 210–219. Hyun YJ, Lee JH, Kim DH. Cloning, overexpression, and characterization of recombinant heparinase III from Bacteroides stercoris HJ-15. Appl Microbiol Biotechnol 2010; 86: 879–890. Cartmell A, Lowe EC, Baslé A, Firbank SJ, Ndeh DA, Murray H et al. How members of the human gut microbiota overcome the sulfation problem posed by glycosaminoglycans. Proc Natl Acad Sci U S A 2017; 114: 7037–7042. Additional Declarations The authors have declared there is NO conflict of interest to disclose Supplementary Files supfig1.tif supfig2.tif suptable.docx Cite Share Download PDF Status: Published Journal Publication published 05 Mar, 2024 Read the published version in Translational Psychiatry → Version 1 posted Editorial decision: revise 02 Jan, 2024 Review # 1 received at journal 29 Sep, 2023 Reviewer # 1 agreed at journal 26 Sep, 2023 Reviewers invited by journal 25 Sep, 2023 Submission checks completed at journal 02 Aug, 2023 First submitted to journal 01 Aug, 2023 Editor assigned by journal 01 Aug, 2023 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3223945","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":235880080,"identity":"9f09b3db-0597-4f5d-9c01-9ff85f9728ee","order_by":0,"name":"peng zheng","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8UlEQVRIiWNgGAWjYPCCA0DMfADKSSBaCxtMKfFaeAyI02LO3nv4BcOfO3Lm/Gs+fnibc5iBnz3HgOHnDtxaLHvOpVkw8DwztpzxdrPk3G2HGSR73hgw9p7BrcXgRo6Z8R+Jw4kbbpzdxswL1AIUMWBmbMOj5f4bMwMGg8P1G26ceQbWYk9Qyw0e4wcMCYcTDM73sEFskSCgxbInxwwYYIcNN9xgMwb6JZ1H4syzgoO9eLSYs58x/sDw57C8wfnDDz+83WYtx9+evPHBT3wOA0ahBJglkQCMGjCCRBM+LcwfwCz+A1D1o2AUjIJRMArQAAB5TVV5UjGOqgAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0002-9864-6832","institution":"The First Affiliated Hospital of Chongqing Medical University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"peng","middleName":"","lastName":"zheng","suffix":""},{"id":235880081,"identity":"07ad7faa-db7a-43a3-9440-30d0ddde14cd","order_by":1,"name":"Peijun Xie","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Peijun","middleName":"","lastName":"Xie","suffix":""},{"id":235880082,"identity":"bb1d6499-05b2-4175-b372-53b0c241cb49","order_by":2,"name":"Xingyu Zhou","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xingyu","middleName":"","lastName":"Zhou","suffix":""},{"id":235880083,"identity":"8f0014e9-f110-44e4-b9bc-40c492376e11","order_by":3,"name":"Yifan Li","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yifan","middleName":"","lastName":"Li","suffix":""},{"id":235880084,"identity":"2f1a7bb8-6efe-4561-86aa-e7a4f164fb08","order_by":4,"name":"Jing Wu","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jing","middleName":"","lastName":"Wu","suffix":""},{"id":235880085,"identity":"e2c3fcaf-a038-4c4f-9d7c-95a1afbaa60e","order_by":5,"name":"Hanping Zhang","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hanping","middleName":"","lastName":"Zhang","suffix":""},{"id":235880086,"identity":"da48247c-cc16-4151-8fea-025175bffc09","order_by":6,"name":"Yu Huang","email":"","orcid":"https://orcid.org/0000-0003-2493-3879","institution":"The First Affiliated Hospital of Chongqing Medical University, Chongqing","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Huang","suffix":""},{"id":235880087,"identity":"52755722-74fc-4e51-b9ea-c47090d3b73c","order_by":7,"name":"Xunmin Tan","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xunmin","middleName":"","lastName":"Tan","suffix":""},{"id":235880088,"identity":"373b4d83-f510-4bef-bca6-2de89f580f3c","order_by":8,"name":"Lu Wen","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lu","middleName":"","lastName":"Wen","suffix":""},{"id":235880089,"identity":"cd08c3ed-c2bc-4b32-b13d-34244b72df2a","order_by":9,"name":"Oluwatayo Israel Olasunkanmi","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Oluwatayo","middleName":"Israel","lastName":"Olasunkanmi","suffix":""},{"id":235880090,"identity":"318aa3cb-35a7-49d6-b48d-57002ebbf632","order_by":10,"name":"Jingjing Zhou","email":"","orcid":"","institution":"Beijing Anding Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jingjing","middleName":"","lastName":"Zhou","suffix":""},{"id":235880091,"identity":"f1577efe-9b7e-4494-ba19-75067bbba620","order_by":11,"name":"Zuoli Sun","email":"","orcid":"","institution":"Beijing Anding Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zuoli","middleName":"","lastName":"Sun","suffix":""},{"id":235880092,"identity":"1e6fb79c-44ac-497e-84af-70551251eca1","order_by":12,"name":"Min Liu","email":"","orcid":"","institution":"Beijing Anding Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Min","middleName":"","lastName":"Liu","suffix":""},{"id":235880093,"identity":"7ee9c251-8446-4e01-bfab-0e91d0249c7b","order_by":13,"name":"Guofu Zhang","email":"","orcid":"","institution":"Capital Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Guofu","middleName":"","lastName":"Zhang","suffix":""},{"id":235880094,"identity":"ac559e37-9974-4357-b8c8-09ec561541bb","order_by":14,"name":"Ying Wang","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ying","middleName":"","lastName":"Wang","suffix":""},{"id":235880095,"identity":"cfd33d5c-89ce-4c42-ad48-5e63c109cd3d","order_by":15,"name":"Peng Xie","email":"","orcid":"https://orcid.org/0000-0002-0081-6048","institution":"The First Affiliated Hospital of Chongqing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Peng","middleName":"","lastName":"Xie","suffix":""},{"id":235880096,"identity":"5713e5ad-4bec-4aed-a9f5-c39991e38220","order_by":16,"name":"Jian Yang","email":"","orcid":"","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jian","middleName":"","lastName":"Yang","suffix":""}],"badges":[],"createdAt":"2023-08-01 10:25:58","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3223945/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3223945/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41398-024-02850-x","type":"published","date":"2024-03-05T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":44034122,"identity":"bfbb049e-a8b1-48b0-bc92-b850fd523099","added_by":"auto","created_at":"2023-10-03 17:42:31","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":175181,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCompositional variation in human gut CAZymes. a,b. \u003c/strong\u003eThe overall characteristics of CAZymes were displayed by Pcoa (bray-curtis distance), internal differences were analyzed with permanova test (permutations=999, Bonferroni \u003cem\u003ep\u003c/em\u003e=0.002). Also, the distance of first and second principal component distance was showed by boxplots (Mann-Whitney U test, \u003cem\u003ep\u003c/em\u003e=0.004). \u003cstrong\u003ec.\u003c/strong\u003e Difference of 6 gut CAZymes diversity index between MDD and HC. \u003cstrong\u003ed. \u003c/strong\u003e83 discriminated CAZymes were identified between two groups (Mann-Whitney U test). \u003cstrong\u003ee.\u003c/strong\u003e The fold change of CAZymes related to plant and animal carbohydrate utilization, plant carbohydrate utilization and mucin glycan and animal to plant carbohydrate utilization in the MDD and HC. The boxplots displayed the respective distributions of three types of CAZymes in metagenome data (Mann-Whitney U test, two-sided). Box-Whisker plot, box=25-75th percentiles, whiskers=5-95th percentiles, horizontal line in box=median.\u003c/p\u003e","description":"","filename":"fig1.png","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/6983a5bfd3fddbb0fe9c3e71.png"},{"id":44034118,"identity":"4e6d52e7-45c5-47f7-aa6f-7354a3ed6934","added_by":"auto","created_at":"2023-10-03 17:42:31","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":118333,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eGut CAZymes features can distinguish MDD and HC. \u003c/strong\u003eUsing random forest model, 9 CAZymes were identified with importance score \u0026gt;1%.\u003cstrong\u003e a.\u003c/strong\u003eVolcano plot for differential CAZymes markers. Significantly regulated metabolites between groups determined by fold change and value of \u003cem\u003ep\u003c/em\u003e(FC\u0026gt;|1.5|, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05). Grey dots represent increased CAZymes in HC; green dots represent increased CAZymes in MDD. \u003cstrong\u003eb.\u003c/strong\u003eThe box plots showed the differences of 9 CAZymes markers (Wilcoxon rank-sum test). \u003cstrong\u003ec.\u003c/strong\u003e A random forest model was constructed and displayed by ROC. In the discovery set, individual signature could discriminate the two groups with area under the curve (AUC) at 0.824, the value in brackets is 95% CI. The diagnostic efficiency was confirmed by 5-fold cross validation test (accuracy: 65.24±7.72%). \u003cstrong\u003ed.\u003c/strong\u003e Correlation-based networks of co-occurring MDD-related CAZymes colored by node affiliation, a co-varying cluster was composed of 6 GHs in MDD subjects. A node stands for an CAZyme and a connection (i.e. edge) stands for a significant (pearson’s r \u0026gt;0.2 or \u0026lt;-0.2, \u003cem\u003ep\u003c/em\u003e\u0026lt;0.05) pairwise correlation. Size of the nodes represents the rpkm of these variables. Edges between nodes indicate pearson’s positive (green) or negative (grey) correlation, edges thickness indicate range of p value (\u003cem\u003ep\u003c/em\u003e\u0026lt;0.05).\u003c/p\u003e","description":"","filename":"fig2.png","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/8772af8f0c9555ea51021db3.png"},{"id":44034119,"identity":"9db86035-61d8-4348-b8d6-d8d23937be42","added_by":"auto","created_at":"2023-10-03 17:42:31","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":59125,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProspective association of CAZymes markers with severity. a,b. \u003c/strong\u003eProspective association of baseline gut CAZymes with HAMD and QIDS score. A total of 45 participants were included in this analysis. Linear mixed-effects model was performed to assess the prospective association of gut CAZymes with the clinical score, adjusting for the demographic (age, gender and educational background), anthropometric (BMI), times of depressive episode and medication. A \u003cem\u003ep\u003c/em\u003e value \u0026lt;0.05 was considered as statistically significant (estimated value β, 95%CI).\u003c/p\u003e","description":"","filename":"fig3.png","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/d5fedfef0a8c935747d94ee2.png"},{"id":52069325,"identity":"ddb9897a-5490-4888-892b-7ab1ea8260fe","added_by":"auto","created_at":"2024-03-06 08:09:00","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":683998,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/3635b2cf-edfa-4575-b7cd-1e8be6ac02c3.pdf"},{"id":44035112,"identity":"dd978b1d-e69d-4703-a6f4-915f5a1d3d70","added_by":"auto","created_at":"2023-10-03 17:50:31","extension":"tif","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":109900,"visible":true,"origin":"","legend":"","description":"","filename":"supfig1.tif","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/ba85f016031648efca41a410.tif"},{"id":44034123,"identity":"9bc3fcd7-cfbb-440f-a07d-7fd8f75e55da","added_by":"auto","created_at":"2023-10-03 17:42:31","extension":"tif","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":85192,"visible":true,"origin":"","legend":"","description":"","filename":"supfig2.tif","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/dc2996a1de6681b23ee31be1.tif"},{"id":44034120,"identity":"c4547dcb-83d5-4bcf-a64a-1b5c4a68fec7","added_by":"auto","created_at":"2023-10-03 17:42:31","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":22727,"visible":true,"origin":"","legend":"","description":"","filename":"suptable.docx","url":"https://assets-eu.researchsquare.com/files/rs-3223945/v1/c6ef11874f41f490f266cc6f.docx"}],"financialInterests":"The authors have declared there is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose","formattedTitle":"Gut microbial CAZymes markers for depression","fulltext":[{"header":"Introduction","content":"\u003cp\u003eMajor depressive disorder (MDD) is a serious and disabling mental illness, affecting up to 15% of the general population [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Currently, there are many theories about the pathogenesis of MDD, but they still can't reveal its whole picture. Current antidepressants developed based on the existing theories can only make 30\u0026ndash;50% of patients achieve clinical remission [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. In addition, clinically, the diagnosis of depression is mainly based on its clinical symptoms and scales. In developing countries, due to lack of professional psychiatrists, and the missed diagnosis and misdiagnosis rate of MDD is still high [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Therefore, it is of great clinical value to reveal the new potential molecular mechanisms of depression and identify the potential biomarkers for MDD.\u003c/p\u003e \u003cp\u003eGut microbiome, an integral part of host biology, harbors about 90 families of carbohydrate-active enzymes (CAZymes) in healthy humans [\u003cspan additionalcitationids=\"CR6\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. By contrast, there are only 4 enzyme families of the human genome, which only degrades starch, trehalose, and sugars [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. In human, the more complex the structure of carbohydrates, the more diverse the enzyme system is needed. Thus, the gut microbiome enables to decompose complex fibers, and convert sugar units into energy to maintain the host\u0026rsquo;s health [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In recent years, increasing clinical and basic studies showed that gut microbiome enables to substantially modulate the brain function and behaviors through microbiome-gut-brain (MGB) axis [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Meanwhile, disturbances of gut microbiome were implicated with development of mental diseases, such as autism, anxiety and schizophrenia [\u003cspan additionalcitationids=\"CR13\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn regarding of MDD, similar phenomenon was also observed. For examples, using the well-matched clinical samples, we found that patients with MDD were characterized by enriched the Bacteroidetes species relative to HC [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], showing a disease specific manner relative to patients with bipolar disorder [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. As Bacteroidetes have more CAZymes-encoding genes [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], we speculate that patients with MDD may be accompanied by alternations of gut microbial CAZymes.\u003c/p\u003e \u003cp\u003eTo test this hypothesis, using the whole-genome shotgun metagenomics method, we compared the microbial CAZymes signatures of patients with MDD and HC. Multivariate statistical method was used to explore the differences of gut microbial CAZymes signatures between the two groups. Meanwhile, the diagnostic and predictive values of candidate CAZymes biomarkers were also evaluated in MDD.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eEthics and participants\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eEthical approval\u003c/strong\u003e \u003cp\u003e was obtained from the Human Research and Ethics Committee of Beijing Anding Hospital (#2017-24), Capital Medical University (China) aligning with the Declaration of Helsinki. The study design complied with all relevant ethical regulations, and all participants provided written informed consent.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eSample collection\u003c/h2\u003e \u003cp\u003eTotally, 311 individuals (aged 18 to 50 years old) were included in this study, including 155 HC and 156 patients with MDD. These samples were obtained from previous metagenomic cohort [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. According to the Chinese version of the Mini-International Neuropsychiatric Interview (MINI), all MDD patients met the standard of DSM-IV. The Hamilton Depression Rating Scale (HAMD) and quick inventory of depressive symptomatology (QIDS) were used to evaluate the depressive severity and manic symptoms of MDD and BD. Patients with HAMD score of 0\u0026ndash;3 is defined as normal, 4\u0026ndash;7 as marginal, 8\u0026ndash;15 as mild, 16\u0026ndash;26 as moderate, and higher than 27 as severe [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. A QIDS score of \u0026lt;\u0026thinsp;6 is defined as normal, 6\u0026ndash;10 as mild, 11\u0026ndash;15 as moderate, and higher than 16 as severe [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Participants who used anti-depressant before collection were excluded in this study. Other exclusion criteria included: (1) History of other mental disorders; (2) suffering from chronic inflammatory disease, diabetes, cardiovascular disease, thyroid disease or cancer; (3) alcohol or drug abuse, acute poisoning; (4) pregnancy or breastfeeding; (5) current administration of antibiotics or long-term use of probiotics.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eDNA extraction and sequencing\u003c/h2\u003e \u003cp\u003eFecal samples were stored at \u0026minus;\u0026thinsp;20\u0026deg;C immediately after collection in the recruitment center, and then wrapped in dry ice and transported to the cryopreservation center. The total genomic DNA of fecal samples was extracted by E.Z.N.A.\u0026reg; Soil DNA Kit (Omega Bio-tek, Norcross, GA, USA) according to the manufacturer\u0026rsquo;s instructions. Then the concentration and purity of the extracted DNA were determined with TBS-380 (Turner BioSystems, Sunnyvale, CA, USA) and NanoDrop 2000 (Thermo-Fisher, Waltham, MA, USA) fluorometry and spectrophotometry respectively, and quality was checked by 1% agarose gel electrophoresis. Paired-end library was constructed after fragmented DNA into an average size of about 300 bp using focused ultrasonication (Covaris M220, Woburn, MA, USA). Then the paired-end sequencing was performed on an Illumina NovaSeq sequencer (Illumina Inc., San Diego, CA, USA). Raw fastq data were quality filtered based on Sickle (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://github.com/najoshi/sickle\u003c/span\u003e\u003cspan address=\"https://github.com/najoshi/sickle\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e), then low-quality reads (length\u0026thinsp;\u0026lt;\u0026thinsp;50 bp, or quality value\u0026thinsp;\u0026lt;\u0026thinsp;20, or having N bases) were removed. Reads were aligned to the human genome by BWA (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://bio-bwa.sourceforge.net\u003c/span\u003e\u003cspan address=\"http://bio-bwa.sourceforge.net\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e), and any hit associated with the reads and their mated reads were removed. Metagenomics data were assembled using MEGAHIT, and contigs with length\u0026thinsp;\u0026ge;\u0026thinsp;300 bp were selected as the final assembled result. Open reading frames (ORFs) from each assembled contig were predicted using MetaGene [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. All predicted genes with a 95% sequence identity were clustered using CD-HIT [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Reads after quality control were mapped to the representative sequences with 95% identity using SOAPaligner (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://soap.genomics.org.cn/\u003c/span\u003e\u003cspan address=\"http://soap.genomics.org.cn/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eAnnotation and initial analysis\u003c/h2\u003e \u003cp\u003eThe non-redundant gene sets were aligning CAZymes database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.cazy.org/\u003c/span\u003e\u003cspan address=\"http://www.cazy.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) based on hmmscan (hmmer 3.0), and the cutoff e-value is set to 1e\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e. Gene expression was reflected by the RPKM value:\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$RPK{M}_{i}=\\frac{{R}_{i}\\times {10}^{6}}{{L}_{i}\\times {\\sum }_{1}^{n}\\left({R}_{j}\\right)}$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eWhere R\u003csub\u003ei\u003c/sub\u003e is the abundance value of Gene\u003csub\u003ei\u003c/sub\u003e in a sample (the reads number aligned to Gene\u003csub\u003ei\u003c/sub\u003e), L\u003csub\u003ei\u003c/sub\u003e represents the nucleotide length of Gene\u003csub\u003ei\u003c/sub\u003e, \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({\\sum }_{1}^{n}\\left({R}_{j}\\right)\\)\u003c/span\u003e\u003c/span\u003erepresents the sum of reads corresponding to all genes in the sample.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eCAZymes analysis\u003c/h2\u003e \u003cp\u003eα-diversity analysis including Simpson 1/D, Shannon H\u0026rsquo;, Menhinick, Margalef and Berger-Parker indexes [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e] was conducted and visualized using the vegan and fossil packages in R, respectively. Principal coordinates analysis (PCoA) was used to visually evaluate the overall difference and similarity of CAZymes between MDD and HC groups [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. The permutational multivariate analysis of variance (PERMANOVA) was used to test group differences. The differential CAZymes between the two groups were identified using wilcoxon rank sum test (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05). For all CAZymes, we used random forest analysis to screen variables according to the proportion of importance\u0026thinsp;\u0026gt;\u0026thinsp;1% as diagnostic markers, then a 5-fold cross-validation was performed to verify the reliability [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The receiver operating characteristic (ROC) curve was obtained (SPSS V.19.0) for the display of the constructed models, then the area under the ROC curve (AUC) was used to designate the ROC effect. Co-occurrence among CAZymes was calculated based on the RPKM by pearson\u0026rsquo;s correlation coefficient (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05). The network layout was calculated and visualized using a circular layout by the Cytoscape software (version 3.1.1).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eLongitudinal analysis\u003c/h2\u003e \u003cp\u003eWe used a linear mixed-effects model to examine the longitudinal association of gut CAZymes with disease severity (HAMD and QIDS), adjusted for the demographic (age, gender and educational background), anthropometric (BMI), times of depressive episode and medication. Associations were expressed as the difference in HAMD or QIDS score (in SD units) per SD difference in each CAZymes, and \u003cem\u003ep\u003c/em\u003e value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eDemographic and clinical data of the recruited subjects.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eIn this study, gut metagenome data from 311 participants were obtained from our previous studies. All patients with MDD (n\u0026thinsp;=\u0026thinsp;118) were unmedicated at baseline, and there was no statistic difference of demographic characteristics in gender, age or BMI between two groups (Table. S1). In addition, an independent validation set (n\u0026thinsp;=\u0026thinsp;75), whose clinical characteristics did not exactly match, was adopted to verify the diagnostic generalizability of CAZymes markers. In addition, 45 MDD subjects were included in the longitudinal follow-up at 3 time points. The clinical scores were used to quantify the efficacy of antidepressants (Table. S2).\u003c/p\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eAlternations of CAZymes signatures in MDD\u003c/h2\u003e \u003cp\u003eHere, we obtained 23578.431\u0026nbsp;million paired-end reads on average based on shotgun metagenomic sequencing. We detected a total of 518 CAZymes, and then included 456 CAZymes (prevalence\u0026thinsp;\u0026gt;\u0026thinsp;10%, mean RPKM\u0026thinsp;\u0026gt;\u0026thinsp;0.01%) for subsequent analysis. Initially, using the multivariate statistical analysis, we sought to explore whether the whole CAZymes signatures of MDD group were significantly different from that in the HC group. Consequently, we observed significant differences of the whole CAZymes signatures between two group based on Pcoa (bray-curtis distance, permutation test, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.002, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ea), and in the first and second principal component (PC1) (Mann-Whitney U test, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.004, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eb). Next, we compared the α-diversity of CAZymes signatures between MDD and HC groups. We found that patients with MDD accompanied by 2 increased indexes (Simpson 1/D and Shannon H\u0026rsquo;) and 4 decreased indexes (Menhinick, Margalef, Berger-Parker and Chao 1) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ec). In addition, using the wilcoxon rank sum test, we totally identified 83 CAZymes responsible for discriminating the MDD and HC groups (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ed). These differentially expressed CAZymes mainly involved in Glycoside Hydrolases (GHs, MDD vs HC, 47.0% vs 14.5%), Glycosyl Transferases (GTs, MDD vs HC, 3.6% vs 4.8%), Polysaccharide Lyases (PLs, MDD vs HC, 12.0% vs 2.4%), Carbohydrate Esterases (CEs, MDD vs HC, 4.8% vs 2.4%) and Carbohydrate-Binding Module (CBMs, MDD vs HC, 3.6% vs 4.8%). Our results showed that the utilization of plant and animal carbohydrates in MDD and HC may be in a balance state. However, compared with the carbohydrate utilization capacity of plants and animals, MDD microbiota shows a higher preference for mucin utilization (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ee).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eDiagnostic gut CAZymes markers for MDD\u003c/h2\u003e \u003cp\u003eA volcano plot with Fold change was applied to identify the specific CAZymes differences between the two groups. The two groups differed in 9 CAZymes markers (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea). Using the random forest model, we identified 9 candidate CAZymes markers for MDD. The results showed that 6GHs (GH20, GH43_24, GH43_4, GH51 and GH95) and 1PL (PL12_1) were significantly increased in MDD group relative to HC group, while 1CBM (CBM37) was decreased (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb and Table. S3). We found that a marker panel including this 9 CAZymes enabled to effectively discriminate the samples from MDD and HC, yielding an AUC value of 0.824 (95% confidence interval (CI), 0.772 to 0.876) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ec). In addition, the 5-fold cross validation was performed to further test the diagnostic performance. Then, a validation set was used to independently confirm the diagnostic performance of this marker panel. Consequently, we found that the this CAZymes panel could discriminate blinded test samples from the two groups with an AUC of 0.736 (95% CI, 0.623\u0026ndash;0.849), respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ec).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eCo-occurrence network of CAZymes markers\u003c/h2\u003e \u003cp\u003eTo explore the potential interaction among CAZymes in MDD, pearson correlation analysis was performed. Here, co-occurrence network depicted the associations (pearson r \u0026lt; -0.2 or \u0026gt;\u0026thinsp;0.2, \u003cem\u003ep\u003c/em\u003e value\u0026thinsp;\u0026lt;\u0026thinsp;0.05) among the MDD-related CAZymes (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ed). Interestingly, 6 GHs including (GH43_24, GH43_4, GH43_7, GH95, GH20 and GH51) generated a covarying cluster, and the members within GHs cluster were negatively correlated to CBM37. In addition, a similar clustering pattern was identified after adding HC samples (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003ePredictive CAZymes markers for MDD\u003c/h2\u003e \u003cp\u003eNext, 45 patients with MDD who were treated with antidepressants were followed up every two weeks (2 weeks, 4 weeks and 6 weeks after treatment) (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003ea). To evaluate the relationship between gut CAZymes and the efficacy of antidepressants, we performed a linear mixed-effects model to examine the longitudinal association of CAZymes markers with MDD disease severity (HAMD, QIDS). A total of 5 gut CAZymes was positively or inversely associated with at least one clinical score (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003ea, b), including 4 GHs (GH43_24, GH43_4, GH20 and GH51) and 1PL (PL12_1). We found that the GH51 (per SD unit) showed a significant inverse association with HAMD (2w: estimated value \u0026minus;\u0026thinsp;0.078, 95% CI: -0.115, -0.040; 4w: estimated value \u0026minus;\u0026thinsp;0.085, 95% CI: -0.131, -0.040; 6w: estimated value \u0026minus;\u0026thinsp;0.048, 95% CI: -0.089, -0.007) and QIDS (2w: estimated value \u0026minus;\u0026thinsp;0.035, 95% CI: -0.069, -0.002; 4w: estimated value \u0026minus;\u0026thinsp;0.041, 95% CI: -0.077, -0.005). Consistently, PL12_1 was also found to be inversely associated with HAMD scores at 4, 6-weeks after antidepressants (4w: estimated value \u0026minus;\u0026thinsp;0.364, 95% CI: -0.631, -0.097; 6w: estimated value \u0026minus;\u0026thinsp;0.341, 95% CI: -0.582, -0.099), and 6-weeks QIDS (6w: estimated value \u0026minus;\u0026thinsp;0.250, 95% CI: -0.455, -0.046). In addition, 2 GHs showed a positive association with 2-week HAMD scores (GH43_24: estimated value 0.063, 95% CI: 0.007, 0.118; GH43_4: estimated value 0.054, 95% CI: 0.002, 0.106). Moreover, GH20 was found to be only related to the 6-week HAMD scores. However, none of GHs or PLs were found to be associated with clinical score at baseline group (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eb).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eClinical and basic studies have shown the link between gut microbiome and MDD. As the fraction of gut microbiome containing the gene coding for CAZymes, here we charactered how the CAZymes changed in the MDD relative to HC. Interestingly, we found that MDD was associated with enriched Glycoside Hydrolases and Polysaccharide Lyases. A random forest model constructed by 9 CAZymes could effectively distinguish patients with MDD and HC, then the diagnostic performance of this CAZymes panel was independently verified. Meanwhile, based on linear mixed-effects analysis, we found that 4 CAZymes could predict the therapeutic effects in the patients treated with antidepressants. Our research provides new ideas for the accurate diagnosis and treatment of depression. The metagenome data suggest that the gut microbiota of MDD have a greater mucin-utilization capacity relative to HC. It may because of the high concentration of \u003cem\u003eBacteroides\u003c/em\u003e in MDD population. In addition, the increased availability of mucin may weaken the mucous layer of the intestinal wall, and some \u003cem\u003eBacteroides\u003c/em\u003e can degrade mucin during survival, such as \u003cem\u003eB. thetaiotaomicron\u003c/em\u003e, \u003cem\u003eB. fragilis\u003c/em\u003e, as a result, harmful molecules in MDD are more likely to cross the gut and enter the circulatory or endocrine system [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAlternations of gut microbiome were closely related to depression. In the past, we and other teams focused on exploring how the gut bacteria and viruses changed in MDD [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. In addition, using fecal bacteria transplantation and probiotic intervention, preliminary evidences showed that disturbances of gut microbiome may attribute to development of depression by regulating the MGB axis\u0026rsquo; metabolism [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].These studies lay a foundation for further study of the role of gut microbiome in depression. Here, we identified the differentially expressed CAZymes in the patients with MDD relative to HC, hoping to further understand the function of gut microbiome in depression from this new point. Here, we found MDD is substantially linked with alternations of CAZymes relative to HC. Compared to HC, the MDD was characterized by enriched Glycoside Hydrolases and Polysaccharide Lyases. Given Bacteroides, especially \u003cem\u003eBacteroides\u003c/em\u003e thetaiotaomicron and \u003cem\u003eBacteroides\u003c/em\u003e ovatus, dedicate about 6% of their genomes to encode these two CAZymes [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. These results suggesting that alternations of \u003cem\u003eBacteroides\u003c/em\u003e species was a hallmark of MDD, which was consistent with our previous studies [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn addition, we found that the CAZymes has potential diagnostic and predictive value in MDD. For example, CAZymes maker panel enable discriminating the MDD and HC with the values of 0.824, suggesting that it has potential clinical transformation value. Clinically, predicting the efficacy of antidepressants remains challenging prior to antidepressant medication, thus inevitably, the trial and error of experience lies in the replacement of new drugs. Here, we found that markers belonging to Glycoside Hydrolases increased in baseline MDD relative to HC. Interestingly, the baseline level of GH51 was negatively correlated with HAMD (2, 4 and 6weeks) and QIDS (2 and 4weeks) scores. Consistently, PL12_1 was also negatively correlated with these two clinical scores of 6weeks. An enzyme (α-L-arabinofuranosidase) in the GH51 family, encoded by two dominant \u003cem\u003eBacteroides\u003c/em\u003e (B. ovatus V975 and B. thetaiotaomicron VPI-5482) [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].Another CAZyme (PL12_1) contains 2 types of heparin lyase, which were found to be encoded by B. stercoris HJ-15 and B. thetaiotaomicron VPI-5482 [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e].These results suggesting alternations between drugs and biological functions of \u003cem\u003eBacteroides\u003c/em\u003e involved in antidepressant effects. Given CAZymes could be detected in feces, it lays a foundation for the development of noninvasive diagnostic and predictive kits.\u003c/p\u003e \u003cp\u003eOur study has the following shortcomings: (1) although a relatively large sample size is used to identify CAZymes as candidate markers, this result still needs to be independently verified by a large multi-center sample; (2) In depth study of the function of CAZymes is expected to further understand the roles of gut microbiome in the pathophysiological mechanisms of MDD; (3) Since CAZymes are mainly involved in the digestion of polysaccharides, it is also worth exploring how to formulate an individualized diet which is more suitable for the microecological health of MDD; (4) Future researches to explore whether intervention of CAZymes has potential therapeutic effects in MDD are required.\u003c/p\u003e \u003cp\u003eIn this study, using well-characterized cross-section and longitudinal clinical samples, we provided evidences that MDD was associated with disturbances of gut CAZymes. Moreover, we found that the CAZymes markers can be used to diagnose the patients with MDD and predict antidepressant effects. Our findings suggest that alternations of CAZymes may be a new entry point to understand the roles of gut microbiome in the development of MDD.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eACKNOWLEDGEMENTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFundings:\u0026nbsp;\u003c/strong\u003eThis work was supported by the Chongqing Science and Technology Committee (cstc2021jcyj-msxmX0096), the Natural Science Foundation Project of China (81971296, 82171523, 82171526 and 82201688), the National Key R\u0026amp;D Program of China (2017YFA0505700), Beijing Talents Project (2020A38), Projects of International Cooperation and Exchanges NSFC (81820108015), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT320002), Chongqing Science \u0026amp;Technology Commission (cstc2019 jcyjjqX0009, cstc2021 jscx-msxm0026), Chongqing Talents Plan for Young Talents (CQYC202105017), Program for Youth Innovation in Future Medicine, Chongqing Medical University, China Postdoctoral Science Foundation (2022MD713717, 2021TQ0396, 2021MD703928).\u0026nbsp;\u003cstrong\u003eAvailability of data and material:\u003c/strong\u003e The metagenomic sequencing data were deposited in the China National GeneBank DataBase (CNGBdb) (https://db.cngb.org/; project ID: CNP0001162). \u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e The study was approved by the Human Research and Ethics Committee of Beijing Anding Hospital of Capital Medical University (#2017-24).\u003cstrong\u003e\u0026nbsp;Conflict of interests:\u003c/strong\u003e The authors declare that they have no conflict of interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHOR CONTRIBUTIONS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDesigned the experiments:\u003c/strong\u003e P.Z. and J.Y. \u003cstrong\u003ePerformed the metagenomic analysis:\u003c/strong\u003e P.J.X., X.Y.Z., Y.F.L., J.W., Y.H. and H.P.Z. \u003cstrong\u003eAnalyzed the metagenomic data:\u003c/strong\u003e P.J.X., X.Y.Z., Y.F.L., O.O., J.J.Z., Z.L.S., M.L., G.F.Z., Y.W. and J.Y. \u003cstrong\u003eDrafted the paper:\u003c/strong\u003e P.J.X., X.Y.Z.\u0026nbsp;\u003cstrong\u003eRevised the paper for intellectual content:\u003c/strong\u003e J.Y. \u0026nbsp;and P.Z.\u003cbr\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136\u0026ndash;151.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J Clin Psychiatry 2020; 81.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137\u0026ndash;151.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaramustafalioğlu O. Major depressive disorder, mental health care, and the use of guidelines in the Middle East. J Clin Psychiatry 2010; 71 Suppl E1: e07.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBhattacharya T, Ghosh TS, Mande SS. Global Profiling of Carbohydrate Active Enzymes in Human Gut Microbiome. PLoS One 2015; 10: e0142038.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTarrah A, Pakroo S, Lemos Junior WJF, Guerra AF, Corich V, Giacomini A. Complete Genome Sequence and Carbohydrates-Active EnZymes (CAZymes) Analysis of Lactobacillus paracasei DTA72, a Potential Probiotic Strain with Strong Capability to Use Inulin. Curr Microbiol 2020; 77: 2867\u0026ndash;2875.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEl Kaoutari A, Armougom F, Gordon JI, Raoult D, Henrissat B. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat Rev Microbiol 2013; 11: 497\u0026ndash;504.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWardman JF, Bains RK, Rahfeld P, Withers SG. Carbohydrate-active enzymes (CAZymes) in the gut microbiome. Nat Rev Microbiol 2022; 20: 542\u0026ndash;556.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eValdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. Bmj 2018; 361: k2179.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE \u003cem\u003eet al.\u003c/em\u003e Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 2015; 64: 1744\u0026ndash;1754.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMorais LH, Schreiber HLt, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 2021; 19: 241\u0026ndash;255.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng P, Zeng B, Liu M, Chen J, Pan J, Han Y \u003cem\u003eet al.\u003c/em\u003e The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv 2019; 5: eaau8317.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharon G, Cruz NJ, Kang DW, Gandal MJ, Wang B, Kim YM \u003cem\u003eet al.\u003c/em\u003e Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell 2019; 177: 1600\u0026ndash;1618.e1617.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression - A systematic review. Clin Psychol Rev 2021; 83: 101943.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang J, Zheng P, Li Y, Wu J, Tan X, Zhou J \u003cem\u003eet al.\u003c/em\u003e Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Sci Adv 2020; 6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng P, Yang J, Li Y, Wu J, Liang W, Yin B \u003cem\u003eet al.\u003c/em\u003e Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Adv Sci (Weinh) 2020; 7: 1902862.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFurukawa TA. Assessment of mood: guides for clinicians. J Psychosom Res 2010; 68: 581\u0026ndash;589.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang PS, Simon GE, Avorn J, Azocar F, Ludman EJ, McCulloch J \u003cem\u003eet al.\u003c/em\u003e Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. Jama 2007; 298: 1401\u0026ndash;1411.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNoguchi H, Park J, Takagi T. MetaGene: prokaryotic gene finding from environmental genome shotgun sequences. Nucleic Acids Res 2006; 34: 5623\u0026ndash;5630.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 2012; 28: 3150\u0026ndash;3152.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCherchi A, Da Pelo S, Ibba A, Mana D, Buosi C, Floris N. Benthic foraminifera response and geochemical characterization of the coastal environment surrounding the polluted industrial area of Portovesme (South-Western Sardinia, Italy). Mar Pollut Bull 2009; 59: 281\u0026ndash;296.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBegum R, Majagi SH, Vijaykumar K. Ants species richness and diversity in relation to different ecological habitat in selected localities of the semi-arid region of Karnataka, India. Environ Monit Assess 2021; 193: 145.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDoan T, Hinterwirth A, Worden L, Arzika AM, Maliki R, Abdou A \u003cem\u003eet al.\u003c/em\u003e Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med 2019; 25: 1370\u0026ndash;1376.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRahimian F, Salimi-Khorshidi G, Payberah AH, Tran J, Ayala Solares R, Raimondi F \u003cem\u003eet al.\u003c/em\u003e Predicting the risk of emergency admission with machine learning: Development and validation using linked electronic health records. PLoS Med 2018; 15: e1002695.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 2020; 69: 2232\u0026ndash;2243.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePearson-Leary J, Zhao C, Bittinger K, Eacret D, Luz S, Vigderman AS \u003cem\u003eet al.\u003c/em\u003e The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats. Mol Psychiatry 2020; 25: 1068\u0026ndash;1079.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2022; 76: 665\u0026ndash;680.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X \u003cem\u003eet al.\u003c/em\u003e Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 2016; 21: 786\u0026ndash;796.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang Z, Li J, Gui X, Shi X, Bao Z, Han H \u003cem\u003eet al.\u003c/em\u003e Updated review of research on the gut microbiota and their relation to depression in animals and human beings. Mol Psychiatry 2020; 25: 2759\u0026ndash;2772.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWhitehead TR. Nucleotide sequences of xylan-inducible xylanase and xylosidase/arabinosidase genes from Bacteroides ovatus V975. Biochim Biophys Acta 1995; 1244: 239\u0026ndash;241.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuis AS, Briggs J, Zhang X, Farnell B, Ndeh D, Labourel A \u003cem\u003eet al.\u003c/em\u003e Dietary pectic glycans are degraded by coordinated enzyme pathways in human colonic Bacteroides. Nat Microbiol 2018; 3: 210\u0026ndash;219.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHyun YJ, Lee JH, Kim DH. Cloning, overexpression, and characterization of recombinant heparinase III from Bacteroides stercoris HJ-15. Appl Microbiol Biotechnol 2010; 86: 879\u0026ndash;890.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCartmell A, Lowe EC, Basl\u0026eacute; A, Firbank SJ, Ndeh DA, Murray H \u003cem\u003eet al.\u003c/em\u003e How members of the human gut microbiota overcome the sulfation problem posed by glycosaminoglycans. Proc Natl Acad Sci U S A 2017; 114: 7037\u0026ndash;7042.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"translational-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"tp","sideBox":"Learn more about [Translational Psychiatry](http://www.nature.com/tp/)","snPcode":"41398","submissionUrl":"https://mts-tp.nature.com/cgi-bin/main.plex","title":"Translational Psychiatry","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Major depressive disorder, Gut microbiome, CAZyme-encoding genes, CAZymes, Biomarker","lastPublishedDoi":"10.21203/rs.3.rs-3223945/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3223945/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eMajor depressive disorder (MDD) is a serious mental illness, characterized by disturbances of gut microbiome, it is required to further explore how the carbohydrate-active enzymes (CAZymes) were changed in MDD. Here, using the metagenomic data from patients with MDD (n\u0026thinsp;=\u0026thinsp;118) and heath controls (HC, n\u0026thinsp;=\u0026thinsp;118), we found that the whole CAZymes signatures of MDD were significantly discriminated from that in HC. α-diversity indexes of the two groups were also significantly different. The patients with MDD were characterized by enriched Glycoside Hydrolases (GHs) and Polysaccharide Lyases (PLs) relative to HC. A panel of makers composed of 9 CAZymes mainly belonging to GHs enabled to discriminate the patients with MDD and HC with AUC of 0.824. In addition, this marker panel could classify blinded test samples from the two groups with an AUC of 0.736. Moreover, we found that baseline 4 CAZymes levels also could predict the antidepressant efficacy after adjusted confounding factors and times of depressive episode. Our findings showed that MDD was associated with disturbances of gut CAZymes, which may help to develop diagnostic and predictive tools for depression.\u003c/p\u003e","manuscriptTitle":"Gut microbial CAZymes markers for depression","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-10-03 17:42:26","doi":"10.21203/rs.3.rs-3223945/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2024-01-02T15:57:13+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2023-09-30T03:44:55+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2023-09-27T00:22:31+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2023-09-25T13:38:19+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2023-08-02T11:03:46+00:00","index":"","fulltext":""},{"type":"submitted","content":"Translational Psychiatry","date":"2023-08-01T10:21:27+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2023-08-01T10:21:27+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"translational-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"tp","sideBox":"Learn more about [Translational Psychiatry](http://www.nature.com/tp/)","snPcode":"41398","submissionUrl":"https://mts-tp.nature.com/cgi-bin/main.plex","title":"Translational Psychiatry","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"28b04e64-cb5a-4c92-8fca-35be2bbc98b7","owner":[],"postedDate":"October 3rd, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":24981520,"name":"Biological sciences/Psychology"},{"id":24981521,"name":"Health sciences/Biomarkers"}],"tags":[],"updatedAt":"2024-03-06T08:08:54+00:00","versionOfRecord":{"articleIdentity":"rs-3223945","link":"https://doi.org/10.1038/s41398-024-02850-x","journal":{"identity":"translational-psychiatry","isVorOnly":false,"title":"Translational Psychiatry"},"publishedOn":"2024-03-05 05:00:00","publishedOnDateReadable":"March 5th, 2024"},"versionCreatedAt":"2023-10-03 17:42:26","video":"","vorDoi":"10.1038/s41398-024-02850-x","vorDoiUrl":"https://doi.org/10.1038/s41398-024-02850-x","workflowStages":[]},"version":"v1","identity":"rs-3223945","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3223945","identity":"rs-3223945","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}